TrialSite News offers this press release directly from Velocity Clinical Research as we are big fans of CEO Dr. Paul Evans and his vision to transcend the network model for a high-quality clinical investigator site operation grown via acquisition and organic activities with a focus on patient safety, quality, and performance.
Velocity Clinical Research is delighted to announce that its senior management team is expanding again this year. Melissa Holbrook joins the Velocity Clinical team as VP Operations and will be responsible for clinical operations at all of Velocity’s sites. Melissa comes to Velocity Clinical after 13 years at IQVIA, where she held positions of increasing responsibility in clinical operations and site management, most recently as VP, Design and Delivery Innovation.
Jeff Jensen hands over the site operations responsibilities to Melissa so he can turn his full attention to Velocity Clinical’s acquisition activity as Sr. VP, Corporate Development. Velocity Clinical is actively pursuing a number of acquisition targets and expects to significantly increase in size by the end of the year.
In preparation for rapid growth, Velocity Clinical has hired a new Director of Human Resources, expanded the finance team, and partnered with an IT provider that is responsible for onboarding new sites into Velocity’s centralized IT framework. These moves are in line with the company’s stated plan for 2019, which is to set up a corporate structure that is ready to bring in new sites and provide support services from day one.
As the clinical research site business continues to consolidate Velocity Clinical Research stands out as one of the only companies to transcend the network model, which is built on loose affiliations and fractured service delivery. Velocity Clinical combines acquisition with organic growth to present sponsors and CROs with access to an expanding site organization that can deliver multiple sites, significantly more patients, unified SOPs, and a single point of contact for all non-patient care functions including feasibility, contracting, patient recruitment, financial activities, and business development.
Dr. Paul Evans, President and CEO, said of Velocity’s expanded management team, “We are so thrilled to have Melissa join us. The breadth and depth of her experience both as a Nurse Practitioner at the site level and managing sites on behalf of sponsors will be invaluable to us as we focus on superior client delivery at all of our sites.”
Melissa Holbrook, VP, Operations, “ I’m thrilled to join Velocity Clinical at an exciting time for the company. As a clinician, I have seen the impact that new and novel therapies can have in improving a patient’s life. Without clinical trials, these new therapies would not be possible. I’m very excited to work with these prestigious sites to continue to meet the needs of our patients, our customers, and the communities we serve.”
Jeffrey Jensen, Senior VP, Corporate Development, “Velocity Clinical’s mission is to build an organization with first-rate research sites and provide them with the tools they need to deliver excellent clinical research and patient care. I am excited to get back on the acquisition side of the business. We are looking for high-quality, high-performance sites that are ready to join a larger organization and take advantage of the benefits of shared resources.”
These experienced professionals are fully committed to helping Velocity create new opportunities to provide outstanding service for its customers, who strive to get drugs to market as quickly and efficiently as possible.
Call to Action: Are you interested in doing business with Velocity Clinical Research? Contact them here.